243PD OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice.
Authors
Delaloge, SConte, P
Im, S
Senkus-Konefka, E
Xu, B
Domchek, S
Masuda, N
Li, W
Tung, N
Armstrong, Anne C
Wu, W
Goessl, C
Runswick, S
Robson, M
Affiliation
Breast Cancer Group, Institut Gustave Roussy, Villejuif, FranceIssue Date
2017-09
Metadata
Show full item recordCitation
243PD OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. 2017, 28(suppl_5): Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdx365.006Additional Links
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx365.006/4108472/243PDOlympiAD-Further-efficacy-outcomes-inType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdx365.006